1. Home
  2. SXI vs RCUS Comparison

SXI vs RCUS Comparison

Compare SXI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Standex International Corporation

SXI

Standex International Corporation

HOLD

Current Price

$247.48

Market Cap

3.3B

Sector

Industrials

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$18.37

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXI
RCUS
Founded
1955
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.2B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
SXI
RCUS
Price
$247.48
$18.37
Analyst Decision
Buy
Strong Buy
Analyst Count
6
15
Target Price
★ $332.40
$41.00
AVG Volume (30 Days)
137.3K
★ 2.2M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
★ 0.59%
N/A
EPS Growth
★ 86.85
N/A
EPS
★ 8.67
N/A
Revenue
★ $604,535,000.00
$247,000,000.00
Revenue This Year
$6.96
N/A
Revenue Next Year
$8.70
N/A
P/E Ratio
$28.26
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$215.62
$17.43
52 Week High
$363.89
$31.74

Technical Indicators

Market Signals
Indicator
SXI
RCUS
Relative Strength Index (RSI) 36.16 29.63
Support Level $238.78 $17.97
Resistance Level $264.25 $24.46
Average True Range (ATR) 10.57 1.61
MACD -2.50 -0.32
Stochastic Oscillator 30.66 12.74

Price Performance

Historical Comparison
SXI
RCUS

About SXI Standex International Corporation

Standex International Corp is a diversified industrial manufacturer with multiple products and services that are used in diverse commercial and industrial markets. The Company operates in four broad business segments: Electronics, Aerospace & Defense (A&D), Scientific, and Engraving & Hydraulics. The Electronics segment generates maximum revenue and is engaged in manufacturing and selling electronic components for applications throughout the end-user market spectrum. The Company has operations in the United States, Europe, Canada, Japan, Singapore, Mexico, Turkey, India, and China. The Company generates maximum revenue from the United States.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: